Arena Pharmaceuticals, Inc.
ARENA PHARMACEUTICALS INC (Form: 3, Received: 03/17/2011 20:43:20)
FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Bielasz Jennifer Kathleen

2. Date of Event Requiring Statement (MM/DD/YYYY)
3/15/2011 

3. Issuer Name and Ticker or Trading Symbol

ARENA PHARMACEUTICALS INC [ARNA]

(Last)        (First)        (Middle)

C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
Sr. Dir. of Accounting & Cont. /

(Street)

SAN DIEGO, CA 92121       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   7666   D  
 

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy)     (1) 1/15/2012   Common Stock   2500   $12.25   D  
 
Employee Stock Option (right to buy)     (2) 7/19/2012   Common Stock   5000   $11.31   D  
 
Employee Stock Option (right to buy)     (3) 1/18/2014   Common Stock   5000   $6.00   D  
 
Employee Stock Option (right to buy)     (4) 10/8/2014   Common Stock   2500   $4.41   D  
 
Employee Stock Option (right to buy)     (5) 1/17/2015   Common Stock   4500   $6.16   D  
 
Employee Stock Option (right to buy)     (6) 1/20/2016   Common Stock   3000   $16.80   D  
 
Employee Stock Option (right to buy)     (7) 7/28/2016   Common Stock   4000   $10.52   D  
 
Employee Stock Option (right to buy)     (8) 2/26/2017   Common Stock   6500   $13.50   D  
 
Employee Stock Option (right to buy)     (9) 3/3/2018   Common Stock   6000   $6.99   D  
 
Employee Stock Option (right to buy)     (10) 3/17/2019   Common Stock   6000   $4.01   D  
 
Employee Stock Option (right to buy)     (11) 3/17/2020   Common Stock   9000   $3.25   D  
 

Explanation of Responses:
( 1)  The options vested in four equal annual installments beginning on January 15, 2003.
( 2)  The options vested in four equal annual installments beginning on July 19, 2003.
( 3)  The options vested in four equal annual installments beginning on June 1, 2004.
( 4)  The options vested in four equal annual installments beginning on October 8, 2005.
( 5)  The options were originally for 6,000 shares of common stock, and they vested in four equal annual installments beginning on June 1, 2005. The holder exercised options to purchase 1,500 shares of common stock.
( 6)  The options vested in four equal annual installments beginning on January 20, 2007.
( 7)  The options vested in four equal annual installments beginning on July 28, 2007
( 8)  The options vested in four equal annual installments beginning on February 26, 2008.
( 9)  The options vest in four equal annual installments, and are exercisable once vested. The first installment became exercisable on March 3, 2009, the second installment became exercisable on March 3, 2010, the third installment became exercisable on March 3, 2011, and the fourth installment vests on March 3, 2012.
( 10)  The options vest in four equal annual installments, and are exercisable once vested. The first installment became exercisable on March 17, 2010, the second installment vests on March 17, 2011, the third installment vests on March 17, 2012, and the fourth installment vests on March 17, 2013.
( 11)  The options vest in four equal annual installments beginning on March 17, 2011, and are exercisable once vested.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Bielasz Jennifer Kathleen
C/O ARENA PHARMACEUTICALS, INC.
6166 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121


Sr. Dir. of Accounting & Cont.

Signatures
Adam S. Chinnock, as Attorney-in-Fact 3/17/2011
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
POWER OF ATTORNEY



      The undersigned hereby constitutes and appoints each of Jack Lief or his successor as Chief Executive Officer, Steven W. Spector or his successor as General Counsel, Adam S. Chinnock or his successor as Assistant General

Counsel, Corporate and Securities, and Carolyn M. Felzer or her successor as Senior Director of Finance and Administration, and each of them acting singly, as the true and lawful attorney-in-fact of the undersigned to:



(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an employee, officer and/or director (or pending employee, officer and/or director) of Arena Pharmaceuticals, Inc. (the "Company"), Form IDs and Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;



(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and



(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this power of attorney (this "Power of Attorney") shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.



 The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.



This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company, attention the foregoing attorneys-in-fact.



This Power of Attorney supersedes any previous power of attorney granted by the undersigned, in the undersigned's capacity as an employee, officer and/or director of the Company, and relating to Form ID, 3, 4, or 5.



      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of March 2011.



   /s/ Jennifer Bielasz

  Jennifer K. Bielasz